Cargando…

PG F(2α) Receptor: A Promising Therapeutic Target for Cardiovascular Disease

Prostaglandins (PGs), a group of key lipid mediators, are involved in numerous physiological and pathological processes including inflammation and cardiovascular homeostasis. Each PG acts on its specific and distinct cell surface G protein-coupled receptors (GPCRs) or peroxisome proliferator-activat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jian, Gong, Yanjun, Yu, Ying
Formato: Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095374/
https://www.ncbi.nlm.nih.gov/pubmed/21607067
http://dx.doi.org/10.3389/fphar.2010.00116
_version_ 1782203641555320832
author Zhang, Jian
Gong, Yanjun
Yu, Ying
author_facet Zhang, Jian
Gong, Yanjun
Yu, Ying
author_sort Zhang, Jian
collection PubMed
description Prostaglandins (PGs), a group of key lipid mediators, are involved in numerous physiological and pathological processes including inflammation and cardiovascular homeostasis. Each PG acts on its specific and distinct cell surface G protein-coupled receptors (GPCRs) or peroxisome proliferator-activated receptors (PPARs). Prostaglandin F(2α) receptor (FP) is required for female reproductive function such as luteolysis and parturition. It has recently been implicated in blood pressure regulation, atherosclerosis and other inflammation-related disorders. The emerging role of FP in cardiovascular diseases is highlighted and potential therapeutic translation is discussed in the current review.
format Text
id pubmed-3095374
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-30953742011-05-23 PG F(2α) Receptor: A Promising Therapeutic Target for Cardiovascular Disease Zhang, Jian Gong, Yanjun Yu, Ying Front Pharmacol Pharmacology Prostaglandins (PGs), a group of key lipid mediators, are involved in numerous physiological and pathological processes including inflammation and cardiovascular homeostasis. Each PG acts on its specific and distinct cell surface G protein-coupled receptors (GPCRs) or peroxisome proliferator-activated receptors (PPARs). Prostaglandin F(2α) receptor (FP) is required for female reproductive function such as luteolysis and parturition. It has recently been implicated in blood pressure regulation, atherosclerosis and other inflammation-related disorders. The emerging role of FP in cardiovascular diseases is highlighted and potential therapeutic translation is discussed in the current review. Frontiers Research Foundation 2010-10-14 /pmc/articles/PMC3095374/ /pubmed/21607067 http://dx.doi.org/10.3389/fphar.2010.00116 Text en Copyright © 2010 Zhang, Gong and Yu. http://www.frontiersin.org/licenseagreement This is an open-access article subject to an exclusive license agreement between the authors and the Frontiers Research Foundation, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are credited.
spellingShingle Pharmacology
Zhang, Jian
Gong, Yanjun
Yu, Ying
PG F(2α) Receptor: A Promising Therapeutic Target for Cardiovascular Disease
title PG F(2α) Receptor: A Promising Therapeutic Target for Cardiovascular Disease
title_full PG F(2α) Receptor: A Promising Therapeutic Target for Cardiovascular Disease
title_fullStr PG F(2α) Receptor: A Promising Therapeutic Target for Cardiovascular Disease
title_full_unstemmed PG F(2α) Receptor: A Promising Therapeutic Target for Cardiovascular Disease
title_short PG F(2α) Receptor: A Promising Therapeutic Target for Cardiovascular Disease
title_sort pg f(2α) receptor: a promising therapeutic target for cardiovascular disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095374/
https://www.ncbi.nlm.nih.gov/pubmed/21607067
http://dx.doi.org/10.3389/fphar.2010.00116
work_keys_str_mv AT zhangjian pgf2areceptorapromisingtherapeutictargetforcardiovasculardisease
AT gongyanjun pgf2areceptorapromisingtherapeutictargetforcardiovasculardisease
AT yuying pgf2areceptorapromisingtherapeutictargetforcardiovasculardisease